Patents Assigned to DENALI THERAPEUTICS, INC.
  • Publication number: 20210009566
    Abstract: The present disclosure relates to methods of making LRRK2-inhibiting, pyrimidinyl-4-aminopyrazole compounds and intermediates of formulae I and IV: The compounds are useful as LRRK2 inhibitors in the treatment of LRRK2 mediated diseases, and as intermediates for their manufacture.
    Type: Application
    Filed: December 19, 2018
    Publication date: January 14, 2021
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Publication number: 20210002260
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Application
    Filed: March 13, 2020
    Publication date: January 7, 2021
    Applicant: Denali Therapeutics Inc.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney
  • Patent number: 10870837
    Abstract: Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-brain barrier are also provided herein.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: December 22, 2020
    Assignee: Denali Therapeutics Inc.
    Inventors: Anastasia Henry, Mihalis Kariolis, Cathal Mahon, Adam P. Silverman, Ankita Srivastava
  • Patent number: 10851088
    Abstract: The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: December 1, 2020
    Assignee: Denali Therapeutics Inc.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Publication number: 20200369746
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, Fc dimers and fusion proteins comprising such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: February 5, 2020
    Publication date: November 26, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • Publication number: 20200317691
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Application
    Filed: February 5, 2020
    Publication date: October 8, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Phillip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Publication number: 20200317749
    Abstract: The present disclosure relates to albumin variants, derivatives and analogs thereof. In particular, provided are albumin variants that bind with increased efficiency to FcRn, including albumin variants that bind with increased efficiency at low pH levels but inefficiently or not at all at neutral pH levels. The albumin variants, derivatives, and analogs have an increased serum half-life when compared to naturally-occurring albumins.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 8, 2020
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Mark S. Dennis, Mihalis Kariolis, Adam Silverman
  • Publication number: 20200289627
    Abstract: Provided herein are methods for transporting agents across the blood brain barrier. In some embodiments, the agents bind to therapeutic targets for the treatment of neurodegenerative diseases. As described herein, the agents are linked to proteins that bind to a transferrin receptor.
    Type: Application
    Filed: February 5, 2020
    Publication date: September 17, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Jennifer Getz, Mihalis Kariolis, Adam P. Silverman, Robert C. Wells, Joy Yu Zuchero
  • Publication number: 20200277373
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody increases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody decreases levels of sTREM2. In some embodiments, the antibody enhances TREM2 activity. In some embodiments, the antibody inhibits TREM2 activity.
    Type: Application
    Filed: September 14, 2018
    Publication date: September 3, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Hang Chen, Gilbert Di Paolo, Rui Hao, Joseph W. Lewcock, Nathan Moerke, Alicia A. Nugent, Rishi Rakhit, Ju Shi, Rinkan Shukla, Ankita Srivastava, Bettina Van Lengerich, Yin Zhang
  • Publication number: 20200277584
    Abstract: Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-brain barrier are also provided herein.
    Type: Application
    Filed: October 1, 2018
    Publication date: September 3, 2020
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Giuseppe ASTARITA, Mark S. DENNIS, Jennifer A. GETZ, Anastasia HENRY, Mihalis KARIOLIS, Cathal MAHON, Adam P. SILVERMAN, Ankita SRIVASTAVA, Julie ULLMAN, Junhua WANG, Joy Yu ZUCHERO
  • Publication number: 20200262890
    Abstract: Provided herein are polypeptides that bind to a blood-brain barrier (BBB) receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a BBB receptor-expressing cell, e.g., for transport across the BBB. Also provided herein are transferrin receptor (TfR) constructs that comprise a monomeric TfR apical domain or one or more portions of the TfR apical domain which have been circularly permuted relative to the full-length TfR sequence.
    Type: Application
    Filed: September 17, 2019
    Publication date: August 20, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mihalis Kariolis, Robert C. Wells
  • Publication number: 20200223935
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: August 16, 2019
    Publication date: July 16, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • Patent number: 10709692
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 14, 2020
    Assignee: Denali Therapeutics Inc.
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Carmela Napolitano, Alfonso Pozzan, Anantha Sudhakar, Zachary K. Sweeney, Federica Tonelli, Javier de Vicente Fidalgo
  • Publication number: 20200216522
    Abstract: In one aspect, antibodies that specifically bind to a human Tau protein are provided. In some embodiments, an anti-Tau antibody recognizes an epitope within residues 111-125 of full-length human Tau, an epitope within residues 251-270 and/or residues 346-360 of full-length human Tau, or an epitope within residues 186-205 of full-length human Tau. In some embodiments, an anti-Tau antibody specifically binds to phosphorylated human Tau, unphosphorylated human Tau, and/or multiple splice isoforms of human Tau. An anti-Tau antibody disclosed herein may also include one or two modified Fc polypeptides.
    Type: Application
    Filed: August 16, 2019
    Publication date: July 9, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Lesley Ann Kane, Do Jin Kim, Joseph W. Lewcock, Suresh Poda, Rishi Rakhit, Rinkan Shukla, Adam P. Silverman
  • Patent number: 10604535
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: March 31, 2020
    Assignee: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Publication number: 20200087319
    Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 19, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Javier De Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Christopher R.H. Hale, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Elena Serra, Zachary K. Sweeney, Arun Thottumkara
  • Publication number: 20200079784
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 12, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Anantha Sudhakar, Zachary K. Sweeney, Javier De Vicente Fidalgo
  • Patent number: 10457717
    Abstract: Provided herein are polypeptides that bind to a blood-brain barrier (BBB) receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a BBB receptor-expressing cell, e.g., for transport across the BBB. Also provided herein are transferrin receptor (TfR) constructs that comprise a monomeric TfR apical domain or one or more portions of the TfR apical domain which have been circularly permuted relative to the full-length TfR sequence.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: October 29, 2019
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Xiaocheng Chen, Mihalis Kariolis, Robert C. Wells
  • Publication number: 20190315723
    Abstract: The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
    Type: Application
    Filed: June 20, 2019
    Publication date: October 17, 2019
    Applicant: Denali Therapeutics Inc.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Publication number: 20190300537
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Application
    Filed: June 7, 2019
    Publication date: October 3, 2019
    Applicant: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cheng Hu, Maksim Osipov, Zachary K. Sweeney, Javier de Vicente Fidalgo, Arun Thottumkara